header-logo header-logo

A bitter pill?

28 February 2014 / Sarah Moore
Issue: 7596 / Categories: Features , Regulatory
printer mail-detail

What impact will the new European Medical Device Regulations have on UK medicine, asks Sarah Moore

At the end of last year, after a year of fierce lobbying by patient groups and manufacturers alike, the new European Medical Device Regulations were finally submitted to the European Parliament and Council for debate and member state approval. When implemented, these new regulations will change legislation that has remained largely untouched for over 20 years.

Ongoing, high profile, prosthetic hip and breast implant litigation has played a key role in galvanising this change. However, exactly what impact these proposed regulatory changes will have, both for patient safety and product litigation in the UK remains to be seen.

EUCOMED, the organisation which speaks for European medical device manufacturers, has warned that the new regulations will stifle innovation and slow down the release of novel products into the market. For product liability lawyers, and others dealing with the after-effects of “novel” products, such as the ASR hip prosthesis, this change in pace has the potential at least to better

If you are not a subscriber, subscribe now to read this content
If you are already a subscriber sign in
...or Register for two weeks' free access to subscriber content

MOVERS & SHAKERS

CBI South-East Council—Mike Wilson

CBI South-East Council—Mike Wilson

Blake Morgan managing partner appointed chair of CBI South-East Council

Birketts—Phillippa O’Neill

Birketts—Phillippa O’Neill

Commercial dispute resolution team welcomes partner in Cambridge

Charles Russell Speechlys—Matthew Griffin

Charles Russell Speechlys—Matthew Griffin

Firm strengthens international funds capability with senior hire

NEWS
The proposed £11bn redress scheme following the Supreme Court’s motor finance rulings is analysed in this week’s NLJ by Fred Philpott of Gough Square Chambers
In this week's issue, Stephen Gold, NLJ columnist and former district judge, surveys another eclectic fortnight in procedure. With humour and humanity, he reminds readers that beneath the procedural dust, the law still changes lives
Generative AI isn’t the villain of the courtroom—it’s the misunderstanding of it that’s dangerous, argues Dr Alan Ma of Birmingham City University and the Birmingham Law Society in this week's NLJ
James Naylor of Naylor Solicitors dissects the government’s plan to outlaw upward-only rent review (UORR) clauses in new commercial leases under Schedule 31 of the English Devolution and Community Empowerment Bill, in this week's NLJ. The reform, he explains, marks a seismic shift in landlord-tenant power dynamics: rents will no longer rise inexorably, and tenants gain statutory caps and procedural rights
Writing in NLJ this week, James Harrison and Jenna Coad of Penningtons Manches Cooper chart the Privy Council’s demolition of the long-standing ‘shareholder rule’ in Jardine Strategic v Oasis Investments
back-to-top-scroll